MTX-474 for Scleroderma

Overseen By Jeffrey Bornstein, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Mediar Therapeutics

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Are You a Good Fit for This Trial?

This trial is for adults over 18 with diffuse cutaneous systemic sclerosis (dcSSc), diagnosed per specific criteria, within certain timeframes from their first symptoms. They must have a minimum lung function and skin available for biopsy, understand the study, and not be pregnant if of childbearing potential.

Inclusion Criteria

I have taken a pregnancy test and it was negative.

My lung function, measured by FVC, is at least 45% of the expected value.

I am willing and able to attend all required study visits and procedures.

What Are the Treatments Tested in This Trial?

Interventions

• MTX-474

Trial Overview

The EncompaSSc trial is testing MTX-474 against a placebo in people with dcSSc. It's a Phase 2 study where participants are randomly assigned to either the drug or placebo without knowing which one they're getting to measure safety and effectiveness.

How Is the Trial Designed?

Group I: MTX-474 Experimental Treatment 1 Intervention

MTX-474

Group II: Placebo Placebo Group 1 Intervention

Placebo

Who Is Running the Clinical Trial?

Mediar Therapeutics

Lead Sponsor

Trials

2

Recruited

140+